We gratefully acknowledge our sponsors for their generous support.
In a changing world, the EC wants the European Union to become a smart, sustainable and inclusive economy. These three mutually reinforcing priorities should help the Union and its Member States deliver high levels of employment, productivity and social cohesion. The new Union programme for research and Innovation, “Horizon 2020” has been designed for that purpose. Running from 2014 to 2020 with a budget of just over €70 billion, Horizon 2020 will support scientific excellence, strengthen industrial leadership in innovation and address major concerns shared by all Europeans, including global societal challenges such as health, demographic change and well-being. International cooperation will be an important cross-cutting priority of Horizon 2020. In addition to Horizon 2020 being fully open to international partnerships, targeted actions with key partner countries and regions will focus on strategic priorities of common interest and mutual benefit
The ANRS is the French National Agency for Research on AIDS and Viral Hepatitis, an autonomous research Agency at Inserm. Its mission is to seek new ways to improve the prevention and treatment of these infections, both in the developed world and in resource limited countries. The Anrs brings together researchers and physicians from all disciplines (basic science, clinical research, public health, economics, prevention ….). At its research sites in Sub-Saharan Africa and in South East Asia, the ANRS mobilizes French and local scientists to collaborate on healthcare issues of paramount importance to these settings. The French ministries of research and health allocate to the ANRS an annual budget of approximately 45 million Euros.
The German Federal Ministry of Education and Research (BMBF) is the German representative in EDCTP. BMBF is a part of the German federal government and supports innovative projects in various research sectors; e.g. in health research, basic sciences, sustainable development, information and communications technologies, life sciences, chemistry and materials science, transport or space research. Funding of research on poverty related and neglected diseases in general as well as that on HIV, TB and Malaria in particular is embedded in the national framework programme Health Research – Scientific Research for the people with a budget of about 140 million € per year which is managed by a specialised project management agency (PT-DLR).
Irish Aid is the Irish Government’s programme for overseas development. The programme is managed by the Development Co-operation Division of the Department of Foreign Affairs and Trade. The work we do in fighting global poverty and hunger is integral to Ireland’s foreign policy.
A central pillar of research in Luxembourg, the Fonds National de la Recherche Luxembourg (FNR) supports researchers in their work, contributes to the development of public research in Luxembourg, encourages international collaborations and the mobility of researchers, and promotes scientific culture. Since 2000, the FNR has implemented various thematic and structural Research Programmes, through which research projects in priority areas for Luxembourg are financed, Accompanying Measures, through which scientific conferences, publications, trainings or other smaller activities may be financed, the allocation of the AFR (Aides à la formation-recherche) Grant Scheme with the objective to financially support PhDs and Postdocs in their training and a strong support of the promotion of scientific culture in Luxembourg.
NACCAP aims to combine excellent scientific research with sustained investments in the R&D capacity in Africa as part of a long-term strategy to fight the diseases of poverty. This new partnership is funded by the Netherlands Ministry of Foreign Affairs (DGIS), as part of the Action Programme for Sustainable Development. NACCAP is managed by the Netherlands Organisation for Scientific Research (NWO).
ISCIII is a public legally autonomous body whose main activities include the promotion of biomedical and other health science research, as well as regulatory issues (e.g. Biobanks) and a main focus in supporting the Spanish National Health System (SNS).
ISCIII via the Fund for Health of Spain (FIS) is the main public body to fund Biomedical and Health Research and Health Research Assessment Projects, Infrastructures and Capacity Building. It is an active actor in the International and European Research Area, e.g. ERA-NETs, ESFRIs, TEC Article 169 (EDCTP, AAL), etc.
Sida, the Swedish International Development Cooperation Agency, is a government agency under the Ministry for Foreign Affairs. Sida’s goal is to contribute to making it possible for poor people to improve their living conditions.
The Swiss Agency for Development and Cooperation (SDC) is Switzerland’s international cooperation agency within the Federal Department of Foreign Affairs (FDFA). In operating with other federal offices concerned, SDC is responsible for the overall coordination of development activities and cooperation with Eastern Europe, as well as for the humanitarian aid delivered by the Swiss Confederation.
The goal of development cooperation is that of reducing poverty. It is meant to foster economic self-reliance and state autonomy, to contribute to the improvement of production conditions, to help in finding solutions to environmental problems, and to provide better access to education and basic healthcare services.
The Medical Research Council supports the best scientific research to improve human health. Its work ranges from molecular level science to public health medicine and has led to pioneering discoveries in our understanding of the human body and the diseases which affect us all.
Aeras is a nonprofit biotech advancing the development of new tuberculosis vaccines for the world.
Aeras is a fully integrated, global nonprofit biotech with capabilities in finance, portfolio management, immunology, assay development, clinical trials, regulatory affairs and policy, advocacy and resource mobilization, as well as in-house capacity to conduct pilot manufacturing. Serving as a critical translational bridge from the bench to the field Aeras has sponsored and conducted over 25 clinical vaccine trials enrolling thousands of subjects, and is a key partner in six active clinical development programs.
Aeras has approximately 160 employees, with offices in Rockville, Maryland; Cape Town, South Africa; and Beijing, China.
Biofabri is a biopharmaceutical company that was founded in 2008 with two lines of business: biological vaccine manufacturing and pharmaceutical manufacturing with over 70 years of experience.
Biofabri has undertaken several R&D projects to develop and manufacture innovative vaccines for human use as the strategic alliance between Biofabri and the University of Zaragoza for the development and manufacture of the first prophylactic vaccine against human tuberculosis, the MTBVAC vaccine.
The new vaccine has been designed by the University of Zaragoza’s prestigious Division of Mycobacterial Research and was developed from a genetically modified bacterial strain using genetic engineering techniques. Biofabri has already produced clinical batches of the vaccine MTBVAC and sponsored the clinical Phase I trial conducted in Switzerland in 2013.
CAAST-Net Plus is a network of 25 partners based in Africa and Europe. Our goal? To strengthen the cooperation in research and innovation between our regions to more effectively tackle the global challenges of health, food security, and climate change. CAAST-Net Plus is supported by the Seventh Framework Programme of the European Union, and builds on the results of the CAAST-Net project (2008-2012). Work with us today to build new bi-regional partnerships for global challenges. Find us on Twitter, Google +, YouTube, Facebook, and LinkedIn; or email enquiries[at]caast-net-plus.org. Together, we can.
Eurice GmbH provides comprehensive support services for the planning, initiation, and implementation of international collaborative projects. In addition to traditional project management, Eurice helps to develop and implement coherent IP strategies and supports consortia through dissemination, networking, training, and capacity building activities.
Eurice is part of the European IPR Helpdesk, an initiative of the EC Directorate General for Enterprise and Industry, offering free of charge, first-line support on IP matters, and a partner in the initiative Fit for Health 2.0 which aims to promote and enhance a sustainable participation of European industry in the health-related sector of Horizon 2020, including EDCTP.
The Global Health Network is a platform for exchanging knowledge, sharing research methods and facilitating collaboration among global health professionals to fuel faster and better evidence to improve health. The Global Health Network functions as an online science park, connecting researchers in a productive, interactive environment where they can access peers, generate research documents, acquire technical expertise, develop new protocols and generally further their research. Through its innovative digital platform, The Global Health Network provides open access to a wide range of free online seminars and courses, downloadable training kits, articles, templates and tools.
The Janssen Global Public Health (Janssen GPH) group complements the groundbreaking science of the Janssen Pharmaceutical companies of Johnson & Johnson with innovative strategies that improve access to medicines, foster collaborations, and support public health solutions to sustainably advance health care worldwide. Current areas of focus include multidrug-resistant tuberculosis (MDR-TB); human immunodeficiency virus (HIV); elephantiasis and river blindness; intestinal worms; and use of mobile technologies (mHealth) to improve health outcomes.
Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of oncology, neurology and immunology.
Pharmalys is an established regional Contract Research Organisation (CRO) with offices in London (UK) and in Dakar (Sénégal). We offer a comprehensive list of services to pharmaceutical and biotech companies and to academic institutions. We provide support in conducting interventional clinical trials, epidemiological studies, data registries, observational studies and social sciences research that take place in Europe and in Africa. We can manage entire projects or offer specific stand-alone services in a proactive and cost-conscious way.
Pharmalys is also dedicated to contributing to capacity building in Africa by providing topic led workshops and on-site training for research professionals and regulators, thereby promoting quality research in the region.
The PATH Malaria Vaccine Initiative (MVI) is a global program of PATH, an international organization that drives transformative innovation to save lives and improve health, especially among women and children. PATH accelerates innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations—that harness its entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, PATH takes innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, they deliver measurable results that disrupt the cycle of poor health.
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
The Global Alliance for TB Drug Development (TB Alliance) is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. The TB Alliance operates with funding from Australia Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, European Commission, Global Health Innovative Technology Fund, Irish Aid, National Institute of Allergy and Infectious Disease, UNITAID, United Kingdom Department for International Development, United States Agency for International Development, and the United States Food and Drug Administration.
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.